
Opinion|Videos|January 27, 2025
Implementing New IgAN Therapies Into Clinical Practice
Key Takeaways
- Biomarkers, including genetic mutations and protein expressions, are vital for predicting disease progression and treatment response.
- Advanced diagnostic techniques are essential for identifying molecular and cellular indicators that inform patient prognosis.
Panelists discuss how the approval of atrasentan is expected to significantly affect the treatment landscape for IgA nephropathy by offering a novel therapeutic option that targets both proteinuria reduction and the underlying immune dysregulation associated with the disease.
Advertisement
Episodes in this series

- Please discuss the clinical implication and the effect on treatment landscape following the approval of atrasentan.
Advertisement
Advertisement
Advertisement
Trending on HCPLive
1
Single Dose of CIDEB siRNA Normalizes Liver Fat in MASLD Through 36 Weeks
2
Lp(a)HORIZON, Oral PCSK9s, and 2027 Lipid Trials, with Kausik Ray, MD, MBChB, MPhil
3
COMP360 Psilocybin NDA Submitted to FDA for Treatment-Resistant Depression
4
What’s New in the 2027 GOLD Report for COPD
5

